Inactive Instrument

Highlights Rubius Therapeutics

Equities

RUBY

US78116T1034

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

North American Morning Briefing : Retail Sales, -2-	23-05-16	DJ
RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-02-27	AQ
Rubius Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
North American Morning Briefing : Stock Futures -3-	23-02-24	DJ
RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-09	AQ
Rubius Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
North American Morning Briefing : Stocks to Steady -2-	22-09-14	DJ
Rubius Therapeutics Announces Strategic Update	22-09-13	CI
RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-09	AQ
Rubius Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-05-10	AQ
Rubius Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability	22-04-08	CI
RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	22-02-25	AQ
Rubius Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Rubius Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-25	CI
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors	22-01-13	CI
Dynamics SPAC Signs Business Combination Deal to Take Senti Biosciences Public; Shares Dip Pre-Bell	21-12-20	MT
Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day	21-12-16	CI
Rubius Therapeutics Reports Wider Than Expected Q3 Net Loss	21-11-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Rubius Therapeutics

Equities

RUBY

US78116T1034

Highlights

Filters